Bamlanivimab vs placebo
Confirmed SARS‐CoV‐2 infection · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab probably leads to lower infection with SARS‐CoV‐2 by day 30 compared with placebo (moderate certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 0.76 [0.59, 0.98]1 study · 966 participantsModerate